← Back to Search

Procedure

Violet Light Therapy for Near-Sightedness

N/A
Recruiting
Research Sponsored by Children's Hospital Medical Center, Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Children must be between 5 to <13 years old
Diagnosis of Myopia (ICD-10-CM Diagnosis Code H52.13) with refractive error:
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured at baseline, and 12 months.
Awards & highlights

Study Summary

This trial investigates how exposure to violet light might reduce the risk of nearsightedness.

Who is the study for?
This trial is for children aged 5 to less than 13 with near-sightedness (myopia) between -1.00D and -6.00D, and astigmatism up to 1.50D in both eyes. They shouldn't have a history of certain eye treatments or conditions like abnormal cornea or myopia treatment with specific drugs, nor plans to move out of the CCHMC area within a year.Check my eligibility
What is being tested?
The study tests whether violet light from two different lamps (Aooshine Bedside Lamp and BIOS Skyview Lamp) can help control the worsening of near-sightedness in children by comparing their effects on myopia progression.See study design
What are the potential side effects?
While not explicitly stated, potential side effects may include discomfort due to bright light exposure, headache, eye strain or sleep disturbances due to changes in lighting environment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My child is between 5 and 12 years old.
Select...
I have been diagnosed with Myopia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured at baseline, and 12 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured at baseline, and 12 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Axial Length
Refractive Error
Visual Acuity

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Violet + / Lens -Experimental Treatment1 Intervention
Subjects use a violet light emitting lamp (device intervention - minimally invasive as it's simply a source of light) with polycarbonate lenses for their refractive correction. The lamp introduces violet light (Violet +) while the polycarbonate lenses block the transmission of violet light through the lenses (Lens -).
Group II: Violet + / Lens +Experimental Treatment1 Intervention
Subjects use a violet light emitting lamp (device intervention - minimally invasive as it's simply a source of light) with CR-39 lenses for their refractive correction. The lamp introduces violet light (Violet +) and the CR-39 lenses allow for the transmission of violet light through the lenses (Lens +).
Group III: Violet - / Lens +Placebo Group1 Intervention
Subjects use a lamp with NO violet light (Violet -) with CR-39 lenses for their refractive correction. CR-39 lenses allow for the transmission of violet light through the lenses (Lens +).

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Near-sightedness include corrective lenses (glasses or contact lenses), orthokeratology (specialized contact lenses worn overnight to reshape the cornea), and refractive surgery (such as LASIK). Corrective lenses work by adjusting the focal point of light entering the eye, allowing it to focus correctly on the retina. Orthokeratology temporarily reshapes the cornea to improve vision during the day. Refractive surgery permanently changes the shape of the cornea to correct the focal point. These treatments are crucial for Near-sightedness patients as they improve visual acuity and reduce the strain on the eyes. The study on violet light suggests that exposure to specific wavelengths of light may influence eye growth and development, potentially offering a non-invasive method to control or reduce the progression of myopia.
Clinical predictors of the optimal spectacle correction for comfort performing desktop tasks.Tinted lenses and related therapies for learning disabilities--a review.Assessing Photoreceptor Status in Retinal Dystrophies: From High-Resolution Imaging to Functional Vision.

Find a Location

Who is running the clinical trial?

Children's Hospital Medical Center, CincinnatiLead Sponsor
815 Previous Clinical Trials
6,530,598 Total Patients Enrolled
~39 spots leftby Sep 2025